title: [Myeloproliferative syndromes].
abstract: Myelodysplastic syndromes [MDS] are clonal disorders of hematopoietic stem cells leading to a deregulation of proliferation and differentiation of the bone marrow cells. Clinically the patients present with symptoms and signs of anemia, thrombocytopenia, and neutropenia. About a third of the patients will develop acute myeloid leukemia. Supportive care is the mainstay of therapy in these mostly elderly patients. G-CSF should only be given in cases of neutropenia and infection, but not prophylactically. Selected patients with severe or transfusion-dependent anemia will respond to treatment with erythropoietin. In advanced MDS aggressive chemotherapy should be considered, while in patients below 50 years of age and an HLA-identical sibling donor allogeneic bone marrow transplantation is the treatment of choice.
authors.affiliation: Medizinische Hochschule, Abteilung für Hämatologie und Onkologie, Hannover.
authors.forename: A
authors.initials: A
authors.lastname: Ganser
mesh_terms: D000368:Aged; D000740:Anemia / Q000175:diagnosis; D016026:Bone Marrow Transplantation; D003937:Diagnosis, Differential; D017707:Erythrocyte Transfusion; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000175:diagnosis* / Q000628:therapy; D009503:Neutropenia / Q000175:diagnosis; D011379:Prognosis; D013921:Thrombocytopenia / Q000175:diagnosis
chemical_list: D016179:Granulocyte Colony-Stimulating Factor